New combo therapy aims to shrink untreatable liver tumors

This study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure that blocks the tumor's blood supply (TACE). The goal is to see if this multi-pronged attack can shrink tumors and improve survival. The trial is small, with only 17 participants, and is being conducted at a single center in China.